AI Article Synopsis
- Upper gastrointestinal cancers have a high mortality rate and poor prognosis, with varying incidence and histology over the past 30 years, leading to improved understanding of their molecular and genetic differences.
- Management involves a multidisciplinary approach, combining surgery, radiotherapy, and systemic treatments tailored to each patient.
- Recent clinical trials have explored the effectiveness of immune checkpoint inhibition (ICI) in these cancers, focusing on the role of molecular characteristics like PD-L1 scores and microsatellite instability, highlighting the complexities and potential benefits of ICI in current treatment strategies.
Article Abstract
Cancers of the upper gastrointestinal tract are a leading cause of cancer-related death world-wide and historically have a poor prognosis. The incidence and histology of these cancers have varied temporally and geographically over the last three decades, with an emerging understanding of the differences in the molecular and genetic profiles across different subgroups. Management of oesophagogastric cancers is by a multidisciplinary team with utilisation of surgery, radiotherapy and systemic treatments in combinations where appropriate. Immune checkpoint inhibition (ICI) has drastically changed the treatment landscape of multiple solid malignancies in the last 5 years. In oesophagogastric cancer, clinical trials have only recently shown activity that is often associated with the molecular characteristics of these tumours, in particular PD-L1 scores or microsatellite instability (MSI-H). This review looks to present the pivotal trials in this space, discuss the complexities between trials that may explain the disparate results and assess the benefit ICI offers in the treatment landscape at present.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276752 | PMC |
| http://dx.doi.org/10.1038/s41416-022-01751-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
This review delves into the evolving landscape of mediated drug delivery, focusing on the versatility of a variety of drug delivery vehicles such as microspheres, microbots, and nanoparticles (NPs). The review also expounds on the critical components and mechanisms for light-mediated drug delivery, including photosensitizers and light sources such as visible light detectable by the human eye, ultraviolet (UV) light, shorter wavelengths than visible light, and near-infrared (NIR) light, which has longer wavelength than visible light. This longer wavelength has been implemented in drug delivery for its ability to penetrate deeper tissues and highlighted for its role in precise and controlled drug release.
View Article and Find Full Text PDFMachine learning-based identification of histone deacetylase-associated prognostic factors and prognostic modeling for low-grade glioma.
Discov Oncol
December 2024
Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China.
Background: Low-grade glioma (LGG) is a slow-growing but invasive tumor that affects brain function. Histone deacetylases (HDACs) play a critical role in gene regulation and tumor progression. This study aims to develop a prognostic model based on HDAC-related genes to aid in risk stratification and predict therapeutic responses.
View Article and Find Full Text PDFInfluence of CYP2C8*3 and ABCG2 C421A genetic polymorphisms on trough concentration and molecular response of imatinib in Egyptian patients with chronic myeloid leukemia.
Cancer Chemother Pharmacol
December 2024
Department of Medical Pharmacology, Faculty of Medicine, Assiut University, Assiut, 71515, Egypt.
Purpose: The treatment landscape for chronic myeloid leukemia (CML) has been revolutionized by the introduction of imatinib, a tyrosine kinase inhibitor, which has transformed the disease from a fatal condition into a manageable chronic illness for a substantial number of patients. Despite this, some individuals do not respond adequately to the treatment, and others may experience disease progression even with continued therapy. This study examined how CYP2C8*3 (G416A; rs11572080) and ABCG2 C421A (rs2231142) single nucleotide polymorphisms (SNPs) affect the plasma trough concentration and therapeutic response of imatinib in Egyptian CML patients.
View Article and Find Full Text PDFEmerging therapeutic approaches for Tourette syndrome and other tic disorders - a systematic review of current clinical trials.
Eur Child Adolesc Psychiatry
December 2024
Department of Neurodevelopmental Disorders, Bethesda Children's Hospital, Budapest, Hungary.
Tourette syndrome and other tic disorders are prevalent neurodevelopmental disorders typically treated with behavioral techniques or pharmacological interventions, primarily antipsychotics. However, many patients do not achieve sufficient response to conventional treatments, underscoring the need for further research in this area. To provide a comprehensive overview of ongoing research activities, we systematically searched the clinical registries of the World Health Organization (WHO) and of the United States National Institutes of Health (NIH) for currently planned or ongoing registered clinical studies.
View Article and Find Full Text PDFThe role of sugar transporter BrSWEET11 in promoting plant early flowering and preliminary exploration of its molecular mechanism.
Plant Cell Rep
December 2024
School of Horticulture and Landscape Architecture, Henan Institute of Science and Technology, Xinxiang, 453003, China.
BrSWEET11 accelerated Arabidopsis thaliana flowering, while silencing Brsweet11 in Brassica rapa delayed flowering relative to controls. BrSWEET11 is involved in sucrose transport after being induced by long-day conditions. SWEETs (Sugars Will Eventually Be Exported Transporters) are sugar outflow transporters that may participate in the regulation of plant flowering.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!